Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like After a Billion+ Loss to Alzheimer's at Medivation, Takes Another Shot at Axovant September 6, 2017 Ex-Genentechers' Denali Scores $1B+ Alzheimer's Deal With Takeda January 4, 2018 Bay Area Biotech Forges Exclusive Pact With Zai Lab for Gastric Cancer Drug Development December 19, 2017
Bay Area Biotech Forges Exclusive Pact With Zai Lab for Gastric Cancer Drug Development December 19, 2017
